8-K: IMAC Holdings Appoints Seasoned Healthcare and Tech Executives to Board of Directors

IMAC Holdings, Inc. announced the appointment of Jason Lobel, a data-driven healthcare and tech entrepreneur, and Saundra Pelletier, a distinguished women's health pharmaceutical executive, to its Board of Directors, effective June 2, 2025.

Summary

• IMAC Holdings, Inc. appointed Jason Lobel and Saundra Pelletier as new members of its Board of Directors on June 2, 2025.
• Jason Lobel is a serial entrepreneur and executive with a strong background in building and scaling data-driven companies across healthcare, retail, and consumer packaged goods.
• Mr. Lobel is currently the CEO and Co-Founder of GenomicMD, a precision health diagnostic company, and previously co-founded SwiftIQ, an AI and analytics platform acquired by PDI Software.
• Saundra Pelletier is an expert in women's health with over three decades of experience in the pharmaceutical industry, having launched brands globally and expanded indications for female healthcare products.
• Ms. Pelletier served as CEO, President, and Executive Director of Evofem Biosciences, Inc. for 10 years, leading it through public market transition, product approvals (PHEXXI, SOLOSEC), and four consecutive years of net sales growth.
• Neither Mr. Lobel nor Ms. Pelletier have family relationships with existing directors or officers, nor any transactions requiring disclosure under Item 404(a) of Regulation S-K.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the appointment of two highly experienced and qualified individuals to the Board of Directors, bringing diverse expertise in healthcare, technology, and corporate leadership. This strengthens the company's governance and strategic capabilities.

Positives

• The appointment of Jason Lobel brings expertise in data-driven company building, AI, and digital transformation, which can enhance IMAC's strategic technological capabilities.
• Saundra Pelletier's extensive experience in women's health, global pharmaceutical launches, and leading a public company (Evofem Biosciences) through growth and product approvals provides valuable strategic and operational insights.
• Both new directors have strong track records of leadership and success in relevant industries, potentially strengthening the board's oversight and strategic direction.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's financial performance or operational outlook, beyond the general positive implications of strengthening the Board.

Management Comments

• The report was signed by Faith Zaslavsky, Chief Executive Officer of IMAC Holdings, Inc., indicating the company's official acknowledgment and reporting of the board appointments.

Industry Context

The appointments reflect a strategic move by IMAC Holdings to bolster its board with diverse expertise relevant to the evolving healthcare and technology landscapes. Jason Lobel's background in data-driven healthcare and AI aligns with the increasing importance of technology in medical diagnostics and patient care. Saundra Pelletier's deep experience in women's health pharmaceuticals and global market expansion could be particularly beneficial as the healthcare industry continues to focus on specialized treatments and broader market access.

Comparison to Industry Standards

• Jason Lobel's experience with GenomicMD and SwiftIQ (an AI/analytics platform) positions him as a valuable asset in an industry increasingly reliant on data-driven insights, comparable to leaders at health tech firms leveraging big data for diagnostics and operational efficiency.
• Saundra Pelletier's tenure as CEO of Evofem Biosciences, where she oversaw product approvals like PHEXXI and SOLOSEC and achieved four consecutive years of net sales growth, demonstrates a strong track record in pharmaceutical leadership, comparable to executives at successful specialty pharmaceutical companies like TherapeuticsMD or Agile Therapeutics, which focus on women's health innovations.
• Her board directorship at Windtree Therapeutics, Inc. (Nasdaq: WINT) further solidifies her standing among experienced public company directors in the biotech and pharmaceutical sectors.

Management Changes

Corporate Governance

Related Party Transactions

• The document explicitly states that there are no family relationships between Mr. Lobel, Ms. Pelletier and any director or officer of the Company, nor are there transactions in which Mr. Lobel or Ms. Pelletier has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: The addition of experienced directors may instill greater confidence in the company's governance and strategic direction, potentially leading to improved long-term value.
• Management: The new directors bring valuable expertise and perspectives that can support and challenge management, fostering better decision-making.
• Employees: A stronger board can lead to more stable and effective company strategies, potentially benefiting employees through clearer direction and growth opportunities.

Next Steps

• The newly appointed directors, Jason Lobel and Saundra Pelletier, will commence their roles on the Board of Directors, contributing to the company's strategic planning and oversight.

Key Dates

Recommendation

Keywords

IMAC Holdings, Board of Directors, Jason Lobel, Saundra Pelletier, Corporate Governance, Healthcare, Pharmaceuticals, Biotechnology, Data Analytics, Digital Transformation, GenomicMD, Evofem Biosciences, Women's Health